دورية
Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1Chromosomal Deletion and Genetic Mutations
| العنوان: | Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1Chromosomal Deletion and Genetic Mutations |
|---|---|
| المؤلفون: | Martín, Iván, Villamón, Eva, Abellán, Rosario, Calasanz, Maria Jose, Irigoyen, Aroa, Sanz, Guillermo F, Such, Esperanza, Mora Casterá, Elvira, Gutiérrez, Míriam, Collado, Rosa, Vara, Míriam, Blanco, Laura, Oiartzabal, Itziar, Álvarez, Sara, Bernal del Castillo, Teresa, Granada, Isabel, Xicoy, Blanca, Zamora, Lurdes, Jerez, Andres, Fernández, Raquel, Calabuig, Marisa, García, Francisca, Sanz, Alejandro, Díez, Rosana, Gil, Ángela, de Paz, Raquel, López, Francisca, González, Teresa, Solano, Carlos, Tormo, Mar |
| المصدر: | Blood; November 2020, Vol. 136 Issue: 1, Number 1 Supplement 1 p1-2, 2p |
| مستخلص: | Introduction:The 20q deletion [del(20q)] is a recurrent chromosomal aberration in myelodysplastic syndromes (MDS) and, as a single abnormality, is associated according to the Revised International Prognostic Scoring System (IPSS-R) with a favorable outcome. However, the breakpoint of del(20q) is very heterogeneous and may cause deletion of the ASXL1gene (20q11.21). This gene is an important epigenetic regulator of hematopoiesis and its mutations have been associated in MDS with a shorter overall survival (OS) and a lower response to azacitidine (AZA). |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2020-139588 |